Isolation and Antibiotic Resistance of Achromobacter xylosoxidans from Non-respiratory Tract Clinical Samples: A 10-year Retrospective Study in a Tertiary-care Hospital in Hungary

Main Article Content

Márió Gajdács


Aims: To assess the prevalence of A. xylosoxidans isolated from non-respiratory tract samples from adult inpatients and outpatients and the antibiotic resistance levels at a tertiary-care teaching hospital in Szeged, Hungary retrospectively, during a 10-year study period.

Study Design: Retrospective microbiological study.

Place and Duration of Study: 1st of January 2008 - 31st of December 2017 at the University of Szeged, which is affiliated with the Albert Szent-Györgyi Clinical Center, a primary- and tertiary-care teaching hospital in the Southern Great Plain of Hungary.

Methodology: Data collection was performed electronically. Antimicrobial susceptibility testing (AST) was performed using disk diffusion method and when appropriate, E-tests on Mueller–Hinton agar plates.

Results: During the 10-year study period, a total of 68 individual A. xylosoxidans isolates were identified (6.8±3.6/year, range: 0-11 isolates). The frequency of isolation in the first half of the study period (2008-2017) was n=22, while in 2013-2017, this number was n=46. The majority of isolates (51 out of 68) were from inpatient departments. 32 out of 68 patients were female (female-to-male ratio: 0.89). The susceptibilities of the respective A. xylosoxidans isolates (n=68) were the following: high levels of susceptibility for imipenem and meropenem (n=63; 92.6%), and moxifloxacin (n=55; 80.9%), while higher rates of resistance were detected for sulfamethoxazole/trimethoprim (susceptible: n=36; 52.9%), ciprofloxacin (susceptible: n=40; 58.8%) and almost all isolates were resistant to ceftazidime (susceptible: n=3; 4.4%) and cefepime (n=2; 2.9%).

Conclusion: The existing literature on Achromobacter infections in the context of non-respiratory human infections is scarce, as the incidence of these pathogens in clinically-relevant syndromes in low. The developments in diagnostic technologies in routine clinical microbiology will probably lead to a shift in the isolation frequency of these bacteria in the future.

Achromobacter xylosoxidans, non-fermenting, Gram-negative, epidemiology, immunocompromised, retrospective, clinical microbiology, medicine.

Article Details

How to Cite
Gajdács, M. (2020). Isolation and Antibiotic Resistance of Achromobacter xylosoxidans from Non-respiratory Tract Clinical Samples: A 10-year Retrospective Study in a Tertiary-care Hospital in Hungary. Journal of Pharmaceutical Research International, 32(1), 1-7.
Original Research Article


Vandamme P, Moore ERB, Cnockaert M, De Brandt E, Svensson-Stadler L, Houf K, Spilker T, LiPuma JJ. Achromobacter animicus sp. nov., Achromobacter mucicolens sp. nov., Achromobacter pulmonis sp. nov. and Achromobacter spiritinus sp. nov., from human clinical samples. Syst Appl Microbiol. 2013;36:1–10.

Gomilla M, Prince-Manzano C, Svensson-Stadler L, Busquets A, Erhardt M, Martínez DL, Lalucat J, Moore ERB. Genotypic and Phenotypic Applications for the Differentiation and Species-Level Identification of Achromobacter for Clinical Diagnoses. Plos One. 2014;9:e114356.

Saiman L, Chen Y, Tabibi S, Gabriel PS, Zhou J, Liu Z, Lai L, Whittier S. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol 2011;39:3942-3945.

Ridderberg W, Bendstrup KEM, Olesen HV, Jensen-Fangel S, Nørskov- Lauritsen N. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J Cyst Fibros. 2011;10:466–469.

Busse HJ, Stolz A. Achromobacter, alcaligenes and related Genera. In: Dworkin M, Falkow S, Rosenberg E, Schleifer KH, Stackebrandt E. (eds) The Prokaryotes. Springer, New York, NY; 2006.

Barragán EP, Pérez SJ, Corbella L, Orellana MÁ, Fernández-Ruíz M. Achromobacter xylosoxidans bacteremia: clinical and microbiological features in a 10-year case series. Rev Esp Quimioter. 2018;31:268-273.

Claassen SL, Reesen JM, Mysliwiec V, Mahlen SD. Achromobacter xylosoxidans Infection Presenting as a Pulmonary Nodule Mimicking Cancer. J Clin Microbiol. 2011;49:2751-2754.

Tena D, Gonzáles-Praetorius A, Pérez-Balsalobre M, Sancho O, Bisquert J. Urinary tract infection due to Achromobacter xylosoxidans: Report of 9 cases. Scand J Infect Dis. 2008;40:84-87.

Bellissimo F, Pinzone MR, Tosto S, Nunnari G, Cacopadro B. Achromobacter xylosoxidans meningitis in an immuno-suppressed patient. Int J Med 2014; 107:65-66.

First Documented Case of Percutaneous Endoscopic Gastrostomy (PEG) Tube-Associated Bacterial Peritonitis due to Achromobacter Species with Literature Review. Case Rep Gast Med; 2020.
ID 4397930.

Krzewinski JW, Nguyen CD, Foster JM, Burns JL. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and achromobacter Alcaligenes xylosoxidans from patients with cystic fibrosis. J Clin Microbiol. 2001; 39:3597–3602.

Wiatr M, Morawska A, Skladzien J, Kedzierska J. Alcaligenes xylosoxidans--a pathogen of chronic ear infection. Otolaryngol Pol. 2005;59:277-280.

Asano K, Tada S, Matsumoto T, Miyase S, Kamio T, Sakurai K, Iida M. A novel bacterium Achromobacter xylosoxidans as a cause of liver abscess: Three case reports. J Hepatol. 2005;43:362-365.

Shinsha T, Oguagha IC. Osteomyelitis caused by Achromobacter xylosoxidans. IDCases. 2015;2:11-12.

de Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros. 2007;6:75–78.

Amoureux L, Bador J, Siebor E, Taillefumier N, Fanton A, Neuwirth C. Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: first French data. J Cyst Fibros. 2013;12:170–176.

Cools P, Ho E, Vranckx K, Schelstraete P, Wurth B, Franckx H, Ieven G, Van Simaey L, Van Daele S, Verhulst S, De Baets F, Vaneechoutte M. Epidemic Achromobacter xylosoxidans strain among Belgian cystic fibrosis patients and review of literature. BMC Microbiol. 2016;16:122.

Moissenet D, Baculard A, Valcin M, Marchand V, Tournier G, Garbarg-Chenon A, Vu-Thien H. Colonization by Alcaligenes xylosoxidans in children with cystic fibrosis: A retrospective clinical study conducted by means of molecular epidemiological investigation. Clin Infect Dis. 1997;24:274–275.

Block JK, Vandemheen KL, Tullis E, Fergusson D, Doucette S, Haase D, Berthiaume Y, Brown N, Wilcox P, Bye P, Bell S, Noseworthy M, Pedder L, Freitag A, Paterson N, Aaron SD. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax. 2006;61:969–974.

Ahmed MS, Nistal C, Jayan R, Kuduvalli M, Anijeet HK. Achromobacter xylosoxidans, an emerging pathogen in catheter-related infection in dialysis population causing prosthetic valve endocarditis: a case report and review of literature. Clin Nephrol 2009;71:350-354.

Schoch PE, Cunha BA. Nosocomial Achromobacter xylosoxidans infections. Infect Contol Hosp Epidemiol 1988;9:84-87.

Weitkamp JH, Tang YW, Hass DW, Midha NK, Crowe JE. Recurrent Achromobacter xylosoxidans Bacteremia Associated with Persistent Lymph Node Infection in a Patient with Hyper–Immunoglobulin M Syndrome. Clin Infect Dis. 2000;31:1183-1187.

Al-Jasser MA, Al-Anazi KA. Complicated septic shock caused by Achromobacter xylosoxidans bacteremia in a patient with acute lymphoblastic leukaemia. Lybian J Med. 2007;2:218-219.

Gajdács M, Urbán E. Resistance trends and Epidemiology of Citrobacter-Entero-bacter-Serratia in Urinary Tract Infections of inpatients and outpatients (RECESUTI): A 10-Year Survey. Medicina (Kaunas). 2019;55:e285.

Gajdács M. Epidemiology and antibiotic resistance trends of pantoea species in a tertiary-care teaching hospital: A 12-year retrospective study. Dev Health Sci. 2019; 2:72-75.

Gajdács M, Burián K, Terhes G. Resistance Levels and Epidemiology of Non-Fermenting Gram-Negative Bacteria in Urinary Tract Infections of Inpatients and Outpatients (RENFUTI): A 10-Year Epidemiological Snapshot. Antibiotics. 2019;8:e143.

Leclercq R, Cantón R, Brown DFJ, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, et al. EUCAST expert rules in antimicrobial susceptibility testing. Clin. Microbiol. Infect. 2013;19:141–160.

Pereira RH, Leão RS, Carvalho-Assef AP, Albano RM, Rodrigues ER, Firmida MC, Folescu TW, Plotkowski MC, Bernardo VG, Marques EA. Patterns of virulence factor expression and antimicrobial resistance in Achromobacter xylosoxidans and Achromobacter ruhlandii isolates from patients with cystic fibrosis. Epidemiol Infect. 2017;145:600-606.

Filipic B, Malesevic M, Vasiljevic Z, Lukic J, Novovic K, Kojic M, Jovcic B. Uncovering differences in virulence markers associated with achromobacter species of CF and Non-CF Origin. Front Cell Infect Microbiol. 2017;7:224.

Edwards BD, Greysson-Wong J, Somayaji R, Waddell B, Whelan FJ, Storey DG, Rabin, HR, Surette MG, Parkins MD. Prevalence and outcomes of achro-mobacter species infections in adults with cystic fibrosis: A North American Cohort Study. J Clin Microbiol. 2017; 55:2074-2085.

Konstantinović N, Ćirković I, Đukić S, Marić V, Božić DD.Biofilm formation of Achromobacter xylosoxidans on contact lens. Acta Microbiol Immunol Hung. 2017; 64:293-300.

Biswas S, Dubus JC, Reynauld-Gaubert M, Stremler N, Rolain JM. Evaluation of colistin susceptibility in multidrug-resistant clinical isolates from cystic fibrosis, France. Eur J Clin Microbiol Infect Dis. 2013;32:1461-1464.

Turton JF, Mustafa N, Shah J, Hampton CV, Pike R, Kenna DT. Identification of Achromobacter xylosoxidans by detection of the blaOXA-114-like gene intrinsic in this species. Diagn Microbiol Infect Dis. 2011;70:408–411.

Gajdács M. The concept of an ideal antibiotics: Implications for drug design. Molecules. 2019;24:e892.